Article
The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications.
Leukemia research - 1 Apr 2013
Quintás-Cardama Alfonso
Abstract excerpt
The acquired recurrent mutation, JAK2 V617F, is the most frequent mutation associated with myeloproliferative neoplasms (MPNs). JAK2 signaling is critical in normal hematopoiesis. Studies using genetically engineered mouse models demonstrated a central role of JAK2 V617F in the pathogenesis of MPNs. Data in animal models showed that JAK2 inhibitors target JAK2 V617F kinase and decrease disease burden. Clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.